Hepatitis D Global Market Report 2025

Description

Hepatitis D, also referred to as hepatitis delta, is a liver infection caused by the hepatitis D virus (HDV). It is regarded as the most severe form of viral hepatitis and occurs exclusively in individuals already infected with the hepatitis B virus (HBV). The hepatitis D virus relies on the hepatitis B virus for replication and survival, making it either a co-infection or a superinfection.

The primary types of hepatitis D are acute and chronic. Acute hepatitis D is a sudden and severe liver infection caused by the hepatitis D virus, often leading to rapid-onset symptoms and potential liver complications. Diagnosis is conducted through various methods, including blood tests, elastography, liver biopsy, serologic testing, and other diagnostic techniques. Medications for hepatitis D are distributed through hospital pharmacies, retail pharmacies, and online pharmacies and are utilized by various end-users, including clinics, hospitals, and other healthcare facilities.

The hepatitis D market research report is one of a series of new reports from The Business Research Company that provides hepatitis D market statistics, including the hepatitis D industry global market size, regional shares, competitors with the hepatitis D market share, detailed hepatitis D market segments, market trends, and opportunities, and any further data you may need to thrive in the hepatitis D industry. This hepatitis D market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The hepatitis D market size has grown steadily in recent years. It will grow from $0.72 billion in 2024 to $0.76 billion in 2025 at a compound annual growth rate (CAGR) of 4.6%. The growth during the historic period can be attributed to limited treatment options, a high prevalence in endemic regions, co-infection with hepatitis B, low awareness and diagnosis rates, and government vaccination programs.

The hepatitis D market size is expected to see steady growth in the next few years. It will grow to $0.90 billion in 2029 at a compound annual growth rate (CAGR) of 4.4%. The growth in the forecast period can be attributed to the expansion of reimbursement policies for novel therapies, rising investment in the healthcare sector, increasing adoption of combination treatments, greater hepatitis B vaccination coverage, and growing public health initiatives. Key trends include advancements in molecular diagnostic tools, a shift toward personalized medicine for liver disease management, the development of novel RNA-based therapies, the expansion of clinical trials for hepatitis D treatments, and the increasing use of telemedicine for hepatitis management.

The rising prevalence of hepatitis B is expected to drive the growth of the hepatitis D market in the coming years. Hepatitis B is a viral infection that affects the liver, causing symptoms such as jaundice, fatigue, and abdominal pain, and can lead to chronic liver disease or liver cancer if left untreated. The increasing number of hepatitis B cases is attributed to factors such as unprotected sexual contact, needle sharing, mother-to-child transmission during childbirth, and insufficient vaccination coverage in certain regions. Hepatitis D depends on the hepatitis B virus for replication, using its surface antigen to infect liver cells, making co-infection with both viruses a significant factor in liver disease progression. For example, in November 2023, the US Department of Health and Human Services reported an 11% rise in newly reported chronic hepatitis B cases in 2022 compared to the previous year. As a result, the growing prevalence of hepatitis B is fueling the expansion of the hepatitis D market.

Leading companies in the hepatitis D market are focusing on developing innovative formulations such as recombinant vaccines to improve immunization efficacy and provide long-lasting protection against the virus. Recombinant vaccines are produced by inserting a gene encoding a viral protein into a host organism, such as bacteria or yeast, allowing the production of the protein to stimulate an immune response without causing the disease. For instance, in December 2022, VBI Vaccines Inc., a US-based biotechnology company, received approval from Health Canada for PreHevbrio [3-antigen Hepatitis B Vaccine (Recombinant)], a vaccine for active immunization against all known subtypes of hepatitis B in adults aged 18 and older. This approval also extends to hepatitis D prevention, as the delta agent responsible for hepatitis D cannot exist without a hepatitis B infection. The decision was based on positive results from two pivotal Phase 3 clinical studies, PROTECT and CONSTANT, which demonstrated higher seroprotection rates with PreHevbrio compared to the single-antigen Engerix-B vaccine.

In October 2023, Gilead Sciences Inc., a US-based biopharmaceutical company, partnered with Assembly Biosciences Inc. to advance the development of next-generation antiviral therapies. This collaboration aims to create innovative treatments for serious viral infections, including hepatitis B, herpesviruses, and hepatitis D. Assembly Biosciences Inc. is a US-based biotechnology company specializing in the development of small-molecule therapeutics targeting serious viral diseases, particularly hepatitis B virus (HBV) and herpes viruses.

Major players in the hepatitis d market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bristol-Myers Squibb Company, Abbott Laboratories, GSK plc, Gilead Sciences Inc., Viatris Inc, VBI Vaccines Inc, Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Dynavax Technologies Corporation, Echosens S.A, Arbutus Biopharma Corporation, PROBIOMED SA de CV, Assembly Biosciences Inc., Replicor Inc., Eiger BioPharmaceuticals Inc, Bluejay Therapeutics Inc, Janssen Pharmaceuticals Inc., Transgene SA, Vir Biotechnology Inc, and Biorex Diagnostics Ltd.

North America was the largest region in the hepatitis D market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in hepatitis D report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the hepatitis D market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The hepatitis D market consists of revenues earned by entities by providing services such as clinical and diagnostic services, public health and awareness campaigns, research and development services, or treatment services. The market value includes the value of related goods sold by the service provider or included within the service offering. The hepatitis D market also includes sales of antiviral drugs, interferon therapies, nucleic acid polymers, liver transplant services, and diagnostic tests. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hepatitis D Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hepatitis d market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hepatitis d ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The hepatitis d market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Type: Acute; Chronic
2) By Diagnosis: Blood Tests; Elastography; Liver Biopsy; Serologic Testing; Other Diagnosis
3) By Distribution Channel: Hospital pharmacies; Retail pharmacies; Online Pharmacies
4) By End-Users: Clinic; Hospital; Other End Users
Subsegments:
1) By Acute: Self-limiting Acute Hepatitis D; Severe Acute Hepatitis D
2) By Chronic: Compensated Chronic Hepatitis D; Decompensated Chronic Hepatitis D
Companies Mentioned: F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; Bristol-Myers Squibb Company; Abbott Laboratories; GSK plc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r34068

1. Executive Summary

2. Hepatitis D Market Characteristics

3. Hepatitis D Market Trends And Strategies

4. Hepatitis D Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Hepatitis D Growth Analysis And Strategic Analysis Framework

5.1. Global Hepatitis D PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Hepatitis D Market Growth Rate Analysis
5.4. Global Hepatitis D Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Hepatitis D Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Hepatitis D Total Addressable Market (TAM)

6. Hepatitis D Market Segmentation

6.1. Global Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Acute
Chronic
6.2. Global Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Blood Tests
Elastography
Liver Biopsy
Serologic Testing
Other Diagnosis
6.3. Global Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital pharmacies
Retail pharmacies
Online Pharmacies
6.4. Global Hepatitis D Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Clinic
Hospital
Other End Users
6.5. Global Hepatitis D Market, Sub-Segmentation Of Acute, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Self-limiting Acute Hepatitis D
Severe Acute Hepatitis D
6.6. Global Hepatitis D Market, Sub-Segmentation Of Chronic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Compensated Chronic Hepatitis D
Decompensated Chronic Hepatitis D

7. Hepatitis D Market Regional And Country Analysis

7.1. Global Hepatitis D Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Hepatitis D Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Hepatitis D Market

8.1. Asia-Pacific Hepatitis D Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Hepatitis D Market

9.1. China Hepatitis D Market Overview
9.2. China Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Hepatitis D Market

10.1. India Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Hepatitis D Market

11.1. Japan Hepatitis D Market Overview
11.2. Japan Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Hepatitis D Market

12.1. Australia Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Hepatitis D Market

13.1. Indonesia Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Hepatitis D Market

14.1. South Korea Hepatitis D Market Overview
14.2. South Korea Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Hepatitis D Market

15.1. Western Europe Hepatitis D Market Overview
15.2. Western Europe Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Hepatitis D Market

16.1. UK Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Hepatitis D Market

17.1. Germany Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Hepatitis D Market

18.1. France Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Hepatitis D Market

19.1. Italy Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Hepatitis D Market

20.1. Spain Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Hepatitis D Market

21.1. Eastern Europe Hepatitis D Market Overview
21.2. Eastern Europe Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Hepatitis D Market

22.1. Russia Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Hepatitis D Market

23.1. North America Hepatitis D Market Overview
23.2. North America Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Hepatitis D Market

24.1. USA Hepatitis D Market Overview
24.2. USA Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Hepatitis D Market

25.1. Canada Hepatitis D Market Overview
25.2. Canada Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Hepatitis D Market

26.1. South America Hepatitis D Market Overview
26.2. South America Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Hepatitis D Market

27.1. Brazil Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Hepatitis D Market

28.1. Middle East Hepatitis D Market Overview
28.2. Middle East Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Hepatitis D Market

29.1. Africa Hepatitis D Market Overview
29.2. Africa Hepatitis D Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Hepatitis D Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Hepatitis D Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Hepatitis D Market Competitive Landscape And Company Profiles

30.1. Hepatitis D Market Competitive Landscape
30.2. Hepatitis D Market Company Profiles
- 30.2.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. GSK plc Overview, Products and Services, Strategy and Financial Analysis

31. Hepatitis D Market Other Major And Innovative Companies

31.1. Gilead Sciences Inc.
31.2. Viatris Inc
31.3. VBI Vaccines Inc
31.4. Alnylam Pharmaceuticals Inc.
31.5. Arrowhead Pharmaceuticals Inc.
31.6. Dynavax Technologies Corporation
31.7. Echosens S.A
31.8. Arbutus Biopharma Corporation
31.9. PROBIOMED SA de CV
31.10. Assembly Biosciences Inc.
31.11. Replicor Inc.
31.12. Eiger BioPharmaceuticals Inc
31.13. Bluejay Therapeutics Inc
31.14. Janssen Pharmaceuticals Inc.
31.15. Transgene SA

32. Global Hepatitis D Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Hepatitis D Market

34. Recent Developments In The Hepatitis D Market

35. Hepatitis D Market High Potential Countries, Segments and Strategies

35.1 Hepatitis D Market In 2029 - Countries Offering Most New Opportunities
35.2 Hepatitis D Market In 2029 - Segments Offering Most New Opportunities
35.3 Hepatitis D Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer